NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 6 February 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dawn Cooper Present for all items
4. Dr Mark Corbett Present for all items
5. Dr Prithwiraj Das Present for all items
6. Dr David Foreman Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Pedro Saramago Goncalves Present for all items
9. John Hampson Present for all items
10. Dr Steven Lloyd Present for all items
11. Iain McGowan Present for all items
12. Ugochi Nwulu Present for all items
13. Stella O’Brien Present for all items
14. Dr Clare Offer Items 1.1 to 5.1.3
15. Amit Parekh Present for all items
16. Dr Kate Ren Present for all items
17. Dr Arpit Srivastava Items 1.1 to 4.2.2
18. Elizabeth Thurgar Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Items 4.1 to 5.2.2

Ian Watson, Associate Director Items 1.1 to 4.2.2

Leena Issa, Project Manager Items 1.1 to 4.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Emilene Coventry, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Linda Landells, Associate Director Items 5.1 to 5.2.2

Kate Moore, Project Manager Items 5.1 to 5.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 5.1.3 to 5.2.2

Emma Bajela, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Max Barnish, Peninsula Technology Assessment Group (PenTAG), University of Exeter Items 1.1 to 4.1.3

Ed Wilson, Peninsula Technology Assessment Group (PenTAG), University of Exeter Items 1.1 to 4.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Mirre Scholte, Kleijnen Systematic Reviews Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Dr Richard Dillon, Consultant Haematologist and Clinical Senior Lecturer, Clinical expert nominated by Servier Laboratories Items 1.1 to 4.1.3

Charlotte Crowley, Policy and Evidence Manager at Leukaemia Care, Patient expert nominated by Leukaemia Care Items 1.1 to 4.1.3

Esther Beswick, Practice Nurse, Patient expert nominated by Leukaemia Care Items 1.1 to 4.1.3

Professor Peter Clark, CDF Clinical Lead, NHS England Items 1.1 to 4.1.3

Professor Perry Elliott, Professor of Cardiovascular Medicine, Clinical expert nominated by Pfizer Items 5.1 to 5.1.3

Professor Philip Hawkins, Professor of Medicine, Clinical expert nominated by the National Amyloidosis Centre Items 5.1 to 5.1.3

Ben Laryea, Patient expert nominated by the UK ATTR Amyloidosis Patients’ Association Items 5.1 to 5.1.3

Paul Pozzo, Chairman of UK ATTR Amyloidosis Patients’ Association, Patient expert, nominated by UK ATTR Amyloidosis Patients’ Association Items 5.1 to 5.1.3

Fiona Marley, NHS Commissioning expert, nominated by NHS England Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Richard Nicholas, welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from Dr Alex Cale, Professor Andrew Renehan, Iftab Akram, Michael Chambers and Satish Venkateshan.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 9 January 2024

### Appraisal of Ivosidenib with azacitidine for untreated IDH1-positive acute myeloid leukaemia [ID6198]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Servier Laboratories.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11167/documents)
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Arpit Srivastava, Kate Ren, and Ugochinyere Nwulu.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11167>

### Appraisal of Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

* 1. Part 1 – Open session
		1. The Chair, Stephen O’Brien, welcomed the invited experts, external assessment group representatives, members of the public, and company representatives from Pfizer.
		2. The Chair asked all committee members and experts, external assessment group representatives, and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11389/documents)
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Pedro Saramago Goncalves, Iain McGowan, and Stella O’Brien.
	2. Part 2 – Closed session (company representatives, professional clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11389>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 5 March 2024 and will start promptly at 09:00am.